NASDAQ:ICCC ImmuCell (ICCC) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free ICCC Stock Alerts $5.14 +0.04 (+0.78%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$5.10▼$5.1450-Day Range$4.90▼$5.3752-Week Range$4.26▼$6.05Volume1,776 shsAverage Volume7,571 shsMarket Capitalization$39.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get ImmuCell alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About ImmuCell Stock (NASDAQ:ICCC)ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Read More ICCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICCC Stock News HeadlinesApril 20, 2024 | americanbankingnews.comImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200-Day Moving Average of $5.02April 10, 2024 | finanznachrichten.deImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 9, 2024 | msn.comImmuCell reports preliminary Q1 sales, stock climbs 7%April 9, 2024 | markets.businessinsider.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024April 9, 2024 | globenewswire.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024February 29, 2024 | finance.yahoo.comImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | seekingalpha.comImmuCell Corporation (ICCC) Q4 2023 Earnings Call TranscriptApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 27, 2024 | globenewswire.comImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023February 16, 2024 | finance.yahoo.comImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023February 16, 2024 | globenewswire.comImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023January 9, 2024 | benzinga.comImmuCell Stock (NASDAQ:ICCC) Dividends: History, Yield and DatesJanuary 9, 2024 | finanznachrichten.deImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023January 8, 2024 | msn.comImmuCell says total sale for year ended December falls 6% Y/YJanuary 8, 2024 | finance.yahoo.comImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023November 15, 2023 | finance.yahoo.comImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | seekingalpha.comImmuCell Corporation (ICCC) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | msn.comImmuCell GAAP EPS of -$0.12, revenue of $5.39MNovember 13, 2023 | finance.yahoo.comImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023November 7, 2023 | finance.yahoo.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023October 5, 2023 | finance.yahoo.comImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023September 5, 2023 | finance.yahoo.comImmuCell Corporation (ICCC) Stock Historical Prices & Data - Yahoo FinanceAugust 29, 2023 | finance.yahoo.comImmuCell Announces Submission of CMC Technical Section to the FDAAugust 11, 2023 | seekingalpha.comImmuCell Corporation (ICCC) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finance.yahoo.comImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023August 8, 2023 | finance.yahoo.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023See More Headlines Receive ICCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/26/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:ICCC CUSIPN/A CIK811641 Webwww.immucell.com Phone(207) 878-2770Fax207-878-2117Employees74Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,780,000.00 Net Margins-33.05% Pretax Margin-33.02% Return on Equity-21.79% Return on Assets-13.16% Debt Debt-to-Equity Ratio0.42 Current Ratio2.73 Quick Ratio0.87 Sales & Book Value Annual Sales$17.47 million Price / Sales2.26 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book1.58Miscellaneous Outstanding Shares7,750,000Free Float7,263,000Market Cap$39.53 million OptionableNot Optionable Beta0.59 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Michael F. Brigham (Age 63)President, CEO, Principal Financial Officer, Treasurer, Secretary & Director Comp: $395.24kMs. Bobbi Jo Brockmann (Age 47)VP of Sales & Marketing and Director Comp: $323.52kElizabeth S. ToothakerDirector of Finance & Administration and ControllerMr. A. Gustavo ScaffaSenior Director of QualityJohn W. ZinckgrafDirector of Product DevelopmentKey CompetitorsAspira Women's HealthNASDAQ:AWHARCA biopharmaNASDAQ:ABIOOncoCyteNASDAQ:OCXCardio DiagnosticsNASDAQ:CDIOTrinity BiotechNASDAQ:TRIBView All CompetitorsInstitutional OwnershipMesirow Financial Investment Management Inc.Bought 12,178 shares on 4/26/2024Ownership: 0.157%View All Institutional Transactions ICCC Stock Analysis - Frequently Asked Questions How have ICCC shares performed in 2024? ImmuCell's stock was trading at $5.09 at the beginning of the year. Since then, ICCC shares have increased by 1.0% and is now trading at $5.14. View the best growth stocks for 2024 here. Are investors shorting ImmuCell? ImmuCell saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 4,500 shares, a decline of 26.2% from the March 31st total of 6,100 shares. Based on an average daily trading volume, of 7,200 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the shares of the company are sold short. View ImmuCell's Short Interest. When is ImmuCell's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ICCC earnings forecast. How can I listen to ImmuCell's earnings call? ImmuCell will be holding an earnings conference call on Friday, May 10th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "2581533". How were ImmuCell's earnings last quarter? ImmuCell Co. (NASDAQ:ICCC) posted its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported ($0.15) EPS for the quarter. The biotechnology company had revenue of $5.10 million for the quarter. ImmuCell had a negative trailing twelve-month return on equity of 21.79% and a negative net margin of 33.05%. What guidance has ImmuCell issued on next quarter's earnings? ImmuCell updated its first quarter 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.3 million-$7.3 million. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE). Who are ImmuCell's major shareholders? ImmuCell's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.16%). View institutional ownership trends. How do I buy shares of ImmuCell? Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ICCC) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
